Nine-valent cervical HPV vaccine is given at an interval of 2 months between the first and second doses, and at an interval of 4 months between the second and third doses. Nine-valent cervical HPV vaccine is a vaccine used to prevent human papillomavirus (HPV) infection, which mainly targets nine types of HPV viruses, namely HPV type 6, 11, 16, 18, 31, 33, 45, 52, and 58, and mainly prevents cervical cancer, vaginal cancer, warts, and anal cancer induced by the persistent infection of the above nine types of viruses. The vaccination of the nine-valent cervical HPV vaccine has clear regulations and is suitable for women aged 16-26 years old. A total of three injections are given throughout the course of the vaccine, which are administered in 0, February and June, i.e., two months between the first and second injections, and four months between the second and third injections. People who are allergic to the ingredients of the vaccine should not be vaccinated, and women who have already developed cervical cancer or pre-cancerous lesions should not be vaccinated.